Ramm Pharma Announces Cease Trade Order

Written by Customer Service on February 28, 2022. Posted in Public Companies.

TORONTO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Ramm Pharma Corp. (CSE: RAMM) (the “Company”). On February 22, 2022, the Company announced that, for reasons set out in its news release of February 22, 2022, the filing of its annual audited financial statements for the year ended October 31, 2021, the accompanying management’s discussion and analysis and the related CEO and CFO certifications (collectively, the “Annual Filings“) would not be filed by the prescribed deadline of February 28, 2022 (the “Deadline”). The Company was not granted a management cease trade order in connection with the delay in filing the Annual Filings, and the Ontario Securities Commission, as principal regulator, notified the Company that a cease trade order (“CTO”) will be issued after the Deadline for failure to file the Annual Filings. As...

ThreeD Capital Inc. Disposes of Securities of Bluesky Digital Assets Corp.

Written by Customer Service on February 28, 2022. Posted in Public Companies.

TORONTO, Feb. 28, 2022 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that through a series of transactions (“Dispositions”), ThreeD and Sheldon Inwentash (the “Joint Actor”) disposed of ownership and control of an aggregate of 8,445,000 common shares (the “Subject Shares”) of Bluesky Digital Assets Corp. (the “Company” or “Bluesky”). The Subject Shares represented approximately 14.3% of all issued and outstanding common shares of the Company. As a result of the Dispositions, the percentage ownership held by ThreeD and the Joint Actor decreased by 14.3% from its last early warning report filed in connection with the acquisition of Bluesky shares,...

Parker to Webcast Investor Meeting March 8 at 9:00 a.m. Eastern Time

Written by Customer Service on February 28, 2022. Posted in Public Companies.

CLEVELAND, Feb. 28, 2022 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that it will webcast a virtual meeting with investors and analysts on Tuesday, March 8, 2022 from 9:00 a.m. to 12:00 p.m. Eastern time. Presentations will be followed by a question and answer session hosted by Parker’s executive leadership. The event will showcase Parker’s ongoing transformation, highlight Parker’s position to capitalize on secular growth trends, and outline the company’s new five-year financial targets through fiscal year 2027. The webcast link for the live meeting will be accessible on the company’s investor website: http://www.phstock.com, and will be archived for one year following the meeting. Parker Hannifin is a Fortune 250 global leader in motion and...

Broadwind Announces $13 Million in New Tower Orders

Written by Customer Service on February 28, 2022. Posted in Public Companies.

CICERO, Ill., Feb. 28, 2022 (GLOBE NEWSWIRE) — Broadwind (NASDAQ: BWEN), a diversified precision manufacturer of specialized components and solutions serving global industries, today announced that the Company has received $13 million in new tower orders from a leading global wind turbine manufacturer. Including these new orders, Broadwind has booked nearly 50% of its full-year 2022 optimal annual tower production capacity. Broadwind expects to schedule additional 2022 bookings over the coming months, as OEM customers seek to secure additional production capacity. “We believe wind tower demand has begun to stabilize, with activity levels expected to gradually improve over the next 24 months,” stated Eric Blashford, President and CEO of Broadwind. “Over the last thirty days, we have received a total of $29 million in tower orders,...

Delta 9 to Open 17th Cannabis Retail Store

Written by Customer Service on February 28, 2022. Posted in Public Companies.

WINNIPEG, Manitoba, Feb. 28, 2022 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”), is pleased to announce the grand opening of its 17th Delta 9 Cannabis retail store, and 12th cannabis store in the Province of Manitoba. Delta 9’s newest retail store is located in the heart of the busiest shopping district in Winnipeg and is scheduled to open on March 1, 2022. Delta 9’s welcoming retail cannabis concept, combined with a focus on convenient and high traffic shopping destinations have been a successful part of the Company’s overall vertical integration strategy. The newest Delta 9 Cannabis Store is situated on Portage Avenue which is also known as part of the Trans Canada highway. This section of Portage Avenue is the focal point for over one million square feet of retail businesses...

CrossAmerica Partners LP Reports Fourth Quarter and Full Year 2021 Results

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

Allentown, PA, Feb. 28, 2022 (GLOBE NEWSWIRE) — CrossAmerica Partners LP Reports Fourth Quarter and Full Year 2021 Results Reported Fourth Quarter 2021 Operating Income of $16.2 million and Net Income of $12.0 million compared to Operating Income of $8.1 million and Net Income of $9.0 million for the Fourth Quarter 2020 Generated Fourth Quarter 2021 Adjusted EBITDA of $37.0 million and Distributable Cash Flow of $31.0 million, which were historical high levels for the Partnership, compared to Fourth Quarter 2020 Adjusted EBITDA of $24.4 million and Distributable Cash Flow of $26.2 million Reported Fourth Quarter 2021 Gross Profit for the Wholesale Segment of $49.4 million compared to $36.8 million of Gross Profit for the Fourth Quarter 2020, an increase of 34% Reported Fourth Quarter 2021 Gross Profit for the Retail Segment of...

Varian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate Update

Written by Customer Service on February 28, 2022. Posted in Mergers And Acquisitions.

NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) — Varian Biopharmaceuticals, Inc. (“Varian Bio”), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. (“SPK”) (NASDAQ: SPK), a special purpose acquisition company (“SPAC”), today announced a joint presentation to discuss the proposed transaction and provide a corporate update. The presentation can be accessed by clicking the link here or by visiting Varian Bio’s investor section of its website at www.varianbio.com. Transaction Overview Pursuant to the merger agreement, Varian Bio will merge with a wholly owned subsidiary of SPK, with Varian Bio being the surviving entity of the merger and a wholly owned subsidiary of SPK. SPK, which currently holds approximately $50 million in gross proceeds from the trust...

CVG Reports Fourth Quarter and Full Year 2021 Results

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

Quarterly Sales of $229 million, EPS $0.08, Adjusted EPS $0.13 Challenging Cost-Price Environment, Higher than Expected Wins New Leadership Team Successfully Transforming CompanyRecord annual sales of $972 million 2021 New Business Wins of $200+ million$500+ million of New Business Wins in last 26 MonthsAligning Reporting Segments with Transformation Agenda NEW ALBANY, Ohio, Feb. 28, 2022 (GLOBE NEWSWIRE) — CVG (NASDAQ: CVGI), a diversified industrial products and services company, today announced financial results for its fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Highlights (Compared with prior-year period, where comparisons are noted) Revenue of $228.9 million, up 6.0% primarily due to material inflation cost pass-through. Operating Income of $6.5 million, up $1.5 million, or 30.0%, resulting...

Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

Presented Phase 1a proof-of-concept data for OP-1250 in metastatic, ER+ / HER2- breast cancer, with demonstrated attractive pharmacokinetics, favorable tolerability and encouraging anti-tumor activity in a heavily pretreated patient population Enrollment in Phase 1b dose expansion on track to complete in Q1 2022; Phase 2 to initiate in H1 2022 Initiated Phase 1b combination study with palbociclib; Additional combination trials with CDK4/6 and PI3Kα inhibitors planned in 2022 Appointed biotech industry veteran Naseem Zojwalla, M.D., as Chief Medical Officer Strong cash, cash equivalents and marketable securities position of $287.3 million as of December 31, 2021 sufficient to fund operations into 2024 SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage...

Forterra Announces Fourth Quarter and Full Year 2021 Results

Written by Customer Service on February 28, 2022. Posted in Earnings Releases And Operating Results.

IRVING, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) — Forterra, Inc. (“Forterra” or “the Company”) (NASDAQ: FRTA), a leading manufacturer of water and drainage infrastructure pipe and products in the United States and Eastern Canada, today announced results for the quarter and full year ended December 31, 2021. Full Year 2021 Highlights Increased net sales by 16.5% to $1,858.3 million as compared to $1,594.5 million last year Increased gross profit by 11.6% to $420.4 million as compared to $376.7 million last year Increased net income by 80.3% to $116.3 million as compared to $64.5 million last year Adjusted EBITDA1 increased by 16.3% to $324.4 million as compared to $279.0 million last year Reduced Net Leverage Ratio2 to 3.1x at year-end from 3.7x a year ago; achieved previously communicated short-term net leverage ratio target of...

Month: February 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice